Upgrade to SI Premium - Free Trial

Cantor Fitzgerald Reiterates Merck (MRK) at Overweight on Earnings, Pipeline and Growth "Remains Underappreciated"

February 3, 2022 7:44 AM
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107.00 price target on Merck (NYSE: MRK), following the company's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles